Valemetostat

Generic Name: Valemetostat

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₃₄ClN_₃O_₄

CAS Number: 1809336-39-7

Unique Ingredient Identifier: 60RD0234VE

Clinical Trials

A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer

Phase 1

Recruiting

Conditions: Extensive-stage Small-cell Lung Cancer

Interventions: Drug: Valemetostat
Drug: Atezolizumab

First Posted Date: 2025-02-04

Last Posted Date: 2025-02-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 24

Registration Number: NCT06807632

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States

and more 4 locations

A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations

Phase 1

Recruiting

Conditions: Non-small Cell Lung Cancer
Lung Cancer

Interventions: Drug: valemetostat tosylate
Drug: pembrolizumab

First Posted Date: 2024-10-16

Last Posted Date: 2024-11-14

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 137

Registration Number: NCT06644768

Locations: 🇺🇸
University of California San Diego (Ucsd)-Moores Cancer Center, La Jolla, California, United States
🇺🇸
California Research Institute, Los Angeles, California, United States
🇺🇸
Valkyrie Clinical Trials, Los Angeles, California, United States

and more 38 locations

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

Phase 2

Recruiting

Conditions: Castration-Resistant Prostate Carcinoma
Stage IVB Prostate Cancer AJCC v8

Interventions: Other: Genetic testing
Drug: Valemetostat Tosylate
Procedure: Magnetic Resonance Imaging
Procedure: Computed Tomography
Procedure: Bone scan
Procedure: FDG-Positron Emission Tomography
Procedure: PSMA PET Scan
Procedure: Biospecimen Collection
Drug: Carboplatin
Drug: Cabazitaxel
Drug: Abiraterone Acetate
Drug: Enzalutamide
Drug: Lutetium Lu 177 Vipivotide Tetraxetan

First Posted Date: 2024-10-09

Last Posted Date: 2025-03-30

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 474

Registration Number: NCT06632977

Locations: 🇺🇸
Banner University Medical Center - Tucson, Tucson, Arizona, United States
🇺🇸
University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
🇺🇸
UC San Diego Health System - Encinitas, Encinitas, California, United States

and more 26 locations

A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC

Phase 1

Not yet recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Valemetostat
Drug: Atezolizumab
Drug: Bevacizumab

First Posted Date: 2024-03-05

Last Posted Date: 2025-05-16

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 45

Registration Number: NCT06294548

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumor

Interventions: Drug: Valemetostat tosylate
Drug: T-DXd
Drug: Dato-DXd

First Posted Date: 2024-02-06

Last Posted Date: 2025-04-10

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 210

Registration Number: NCT06244485

Locations: 🇺🇸
City of Hope At Orange County Lennar Foundation Cancer Center, Irvine, California, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center (Mskcc) - New York, New York, New York, United States
🇺🇸
Clinical Research Alliance, Westbury, New York, United States

and more 28 locations

Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS

Phase 1

Not yet recruiting

Conditions: Squamous Non-small Cell Lung Cancer
Lung Cancer
Sinonasal Cancer
Head and Neck Squamous Cell Carcinoma
Head and Neck Cancer
Head and Neck Carcnimona

Interventions: Drug: pembrolizumab
Drug: valemetostat

First Posted Date: 2023-05-30

Last Posted Date: 2025-05-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 47

Registration Number: NCT05879484

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma

Phase 1

Recruiting

Conditions: Lymphoma

Interventions: Drug: Rituximab
Drug: Lenalidomide
Drug: Valemetostat

First Posted Date: 2023-01-13

Last Posted Date: 2025-04-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 60

Registration Number: NCT05683171

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer

Phase 1

Recruiting

Conditions: Breast Cancer

Interventions: Drug: Valemetostat
Drug: Trastuzumab deruxtecan

First Posted Date: 2022-12-01

Last Posted Date: 2025-02-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 37

Registration Number: NCT05633979

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma

Phase 2

Active, not recruiting

Conditions: Lymphoma, B-Cell

Interventions: Drug: Valemetostat tosylate

First Posted Date: 2021-04-13

Last Posted Date: 2025-01-24

Lead Sponsor: The Lymphoma Academic Research Organisation

Target Recruit Count: 141

Registration Number: NCT04842877

Locations: 🇧🇪
University Hospital Gent, Gent, Belgium
🇧🇪
CHU Mont-Godinne, Yvoir, Belgium
🇫🇷
CHU de Montpellier, Montpellier, France

and more 19 locations

Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

Phase 2

Active, not recruiting

Conditions: Relapsed/Refractory Peripheral T-Cell Lymphoma
Adult T Cell Leukemia/Lymphoma

Interventions: Drug: Valemetostat Tosylate

First Posted Date: 2021-01-11

Last Posted Date: 2024-07-22

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 155

Registration Number: NCT04703192

Locations: 🇺🇸
Weill Cornell Medicine, New York, New York, United States
🇺🇸
City Of Hope National Medical Center, Duarte, California, United States
🇺🇸
Stanford University Medical Center - Cancer Clinical Trials Office - ONCOLOGY, Palo Alto, California, United States

and more 57 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy